These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11534565)

  • 1. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome.
    Gallagher J; Fisher C; Sherman B; Munger M; Meyers B; Ellison T; Fischkoff S; Barchuk WT; Teoh L; Velagapudi R
    Intensive Care Med; 2001 Jul; 27(7):1169-78. PubMed ID: 11534565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
    Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
    Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study.
    Reinhart K; Menges T; Gardlund B; Harm Zwaveling J; Smithes M; Vincent JL; Tellado JM; Salgado-Remigio A; Zimlichman R; Withington S; Tschaikowsky K; Brase R; Damas P; Kupper H; Kempeni J; Eiselstein J; Kaul M
    Crit Care Med; 2001 Apr; 29(4):765-9. PubMed ID: 11373466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group.
    Fisher CJ; Opal SM; Dhainaut JF; Stephens S; Zimmerman JL; Nightingale P; Harris SJ; Schein RM; Panacek EA; Vincent JL
    Crit Care Med; 1993 Mar; 21(3):318-27. PubMed ID: 8440099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.
    Cohen J; Carlet J
    Crit Care Med; 1996 Sep; 24(9):1431-40. PubMed ID: 8797612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.
    Rice TW; Wheeler AP; Morris PE; Paz HL; Russell JA; Edens TR; Bernard GR
    Crit Care Med; 2006 Sep; 34(9):2271-81. PubMed ID: 16810105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
    Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
    Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E; Reinhart K; Svoboda P; Seibert A; Olthoff D; Dal Nogare A; Postier R; Hempelmann G; Butler T; Martin E; Zwingelstein C; Percell S; Shu V; Leighton A; Creasey AA
    Crit Care Med; 2001 Nov; 29(11):2081-9. PubMed ID: 11700399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Afelimomab.
    Vincent JL
    Int J Clin Pract; 2000 Apr; 54(3):190-3. PubMed ID: 10829362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated administration of a F(ab')2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: effects on the cardiovascular system and cytokine levels.
    Boekstegers P; Weidenhöfer S; Zell R; Pilz G; Holler E; Ertel W; Kapsner T; Redl H; Schlag G; Kaul M
    Shock; 1994 Apr; 1(4):237-45. PubMed ID: 7735957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
    Pallua N; Low JF; von Heimburg D
    Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin in septic patients: effects on cardiovascular and renal function and its relationship to proinflammatory cytokines.
    Tschaikowsky K; Sägner S; Lehnert N; Kaul M; Ritter J
    Crit Care Med; 2000 Jun; 28(6):1854-60. PubMed ID: 10890632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure.
    Abraham E; Naum C; Bandi V; Gervich D; Lowry SF; Wunderink R; Schein RM; Macias W; Skerjanec S; Dmitrienko A; Farid N; Forgue ST; Jiang F
    Crit Care Med; 2003 Mar; 31(3):718-28. PubMed ID: 12626975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
    Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.